Medicinal chemists have a role to play in ensuring that the intersection between the synthetic and the organic chemistry and pharmacology based on other biological perspectives becomes successful (Wermuth, 2008). The chemists deal with drug discovery and development but have to ensure that their designs align with the pharmacology and organic needs of the various diseases affecting people in the society.
The drug development business focuses on making profits while meeting the needs of the people in the society. Prevention of cancer does not fall under their activities since profits lie at the later stages of cancer treatment (Wermuth, 2008). Therefore, drug development will aim at meeting the needs of patients at stages where they will have maximum profits thus striking off cancer prevention from the list.
Some of the drugs to watch in 2016 include;
Obeticholic acid- The drug targets the treatment of the chronic liver diseases including biliary cirrhosis
Emtricitabine + tenofovir alafenamide (F/TAF)- The drug is used for the treatment of HIV-1 Infection
Tenofovir alafenamide + emtricitabine + rilpivirine (R/F/TAF- The drug targets the treatment of HIV-1 infection (Thomson Reuters, 2015)
MK-5172A (grazoprevir + elbasvir)- The drug is used for the treatment of HCV infection
Venetoclax- The medicine treats chronic lymphocytic leukemia
Nuplazid (pimavanserin)- A drug used in the treatment of Parkinson’s disease psychosis
Uptravi (selexipag)- A drug used in the treatment of pulmonary arterial hypertension
The prescriptions to watch report is written for the consumers and all the people who purchase the drugs related to the stated diseases. The drug development business aims at making sure that the demand for the illnesses is high and they will target the later stages of the infection (Thomson Reuters, 2015). Therefore, one should be careful when purchasing the drugs and should look for alternatives that have lower prices but equally effective.
Some of the problems associated with drug development revolve around failures such as translational when using the animal models, the inability to rely on the published data and lack of collaboration among the academia, the industry and the government (Thomson Reuters, 2015). Drug development requires the participation of the various groups, and if this does not happen, then the activity may not end up successful.
The R divisions have focused on a different strategy to overhaul the current models. In this case, drug development focuses on some of the rare conditions that affect small groups of people in the world (Thomson Reuters, 2015).
The drug companies using research and development are at risk of not acquiring sufficient information that would help them in making the best quality drugs that fetch high prices in the market (Wermuth, 2008). R may not offer the required information or qualifications for drug development activities.